诺和诺德警告美国定价压力与专利到期风险

Core Viewpoint - Novo Nordisk (NVO) shares fell by 6.3% following warnings about pricing pressures in the U.S. and risks associated with patent expirations [1][2] Group 1: Pricing Pressure and Market Competition - CEO Mike Doustdar indicated that by 2026, the company will face increasing pricing pressures in a competitive market [1][2] - The global GLP-1 market is expected to continue expanding, but U.S. policies, particularly the "Most Favored Nation" pricing initiative pushed by former President Trump, will significantly impact revenues [1][2] Group 2: Sales Forecast and Historical Context - The latest guidance suggests that Novo Nordisk will experience its first annual sales decline in nine years, with the last occurrence being in 2017 due to a price war in the U.S. insulin market [1][2]